2. Academic Validation
  3. In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators

  • Br J Pharmacol. 2025 Aug 20. doi: 10.1111/bph.70176.
Emanuela Pesce 1,  Valeria Tomati 1,  Valeria Capurro 1,  Mariateresa Lena 2,  Cristina Pastorino 1,  Miro Astore 3,  Serdar Kuyucak 3,  Benoit Chevalier 4 5,  Elvira Sondo 1,  Federico Cresta 6,  Alice Dighero 1,  Vito Terlizzi 7,  Cristina Fevola 7,  Stefano Costa 8,  Maria Cristina Lucanto 8,  Valeria Daccò 9,  Laura Claut 9,  Francesca Ficili 10,  Benedetta Fabrizzi 11,  Renata Bocciardi 1 2,  Federico Zara 1 2,  Carlo Castellani 6,  Luis J V Galietta 12,  Shafagh A Waters 13 14 15 16,  Alexandre Hinzpeter 4 5,  Nicoletta Pedemonte 1
Affiliations

Affiliations

  • 1 UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • 2 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • 3 School of Physics, The University of Sydney, Sydney, New South Wales, Australia.
  • 4 INSERM, CNRS, Institut Necker Enfants Malades, Paris, France.
  • 5 Université Paris-Cité, Paris, France.
  • 6 UOSD Centro Fibrosi Cistica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • 7 Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy.
  • 8 Centro Hub Fibrosi Cistica, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy.
  • 9 Department of Pediatrics, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • 10 Cystic Fibrosis Center, Ospedale Giovanni Di Cristina, Palermo, Italy.
  • 11 Cystic Fibrosis Regional Centre, Unit of Emerging and Immunosuppressed Infectious Diseases, Department of Gastroenterology and Transplantation, Azienda Ospedaliero-Universitaria 'Ospedali Riuniti', Ancona, Italy.
  • 12 Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
  • 13 School of Clinical Medicine, Discipline of Paediatrics and Child Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • 14 Molecular and Integrative Cystic Fibrosis Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
  • 15 School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • 16 Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, New South Wales, Australia.
PMID: 40831301 DOI: 10.1111/bph.70176
Abstract

Background and purpose: Cystic fibrosis (CF) is due to loss-of-function variants of the CF transmembrane conductance regulator (CFTR) channel. The most effective treatment for people with CF carrying the F508del mutation is the triple combination of elexacaftor-tezacaftor-ivacaftor (ETI). ETI can correct the underlying defect(s) in Other CFTR mutants. The use of disease-relevant predictive models such as patient-derived human nasal epithelial cells allow to investigate the response to CFTR modulators of specific genotypes, possibly supporting patients' access to treatment.

Experimental approach: Using computational, biochemical and functional methodologies, a detailed analysis of selected variants in the intracellular loop 4 (ICL4) to understand their impact on CFTR structure and function.

Key results: Mutations affecting L1065, R1066 and L1077 compromise structural stability of CFTR. Analyses of single variants expressed heterologously in immortalized bronchial cells showed that, upon ETI, rescued activity for both L1065P and R1066C was close to 50% of the wild-type CFTR activity. Biochemical studies of ICL4 variants expression pattern in CFBE41o-cells, following treatment for 24 h, demonstrate the appearance of the mature, fully glycosylated band, with no changes in the immature band. Finally, our study provides evidence in primary nasal cells from a cohort of people with CF that L1065P and R1066C can be effectively rescued by ETI up to 25%-45% of the activity measured in non-CF epithelia.

Conclusion and implications: Although the observed rescue for L1065P and R1066C was smaller than that of the F508del, it should fall in a range predicted, by various studies, to provide a clinical benefit.

Keywords

CFTR modulators; chloride channel; correctors; personalized medicine; potentiators; predictive models; theratyping.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z